Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 1/20 | 0.43 |
| ▸ | UBE2M | P61081 | 1/20 | 0.43 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | AGER | Q15109 | 3/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | CETP | P11597 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6482118 | 1.00 | CCR5 (0.43) | CCR5UBE2MDCUN1D1CYP2D6SLC6A2 | |
| SCHEMBL4799331 | 0.87 | AGER (0.44) | UBE2MDCUN1D1OPRM1ESR2AGER | |
| SCHEMBL4799335 | 0.87 | AGER (0.44) | UBE2MDCUN1D1OPRM1ESR2AGER | |
| SCHEMBL4801250 | 0.87 | HSD11B1 (0.48) | UBE2MDCUN1D1OPRM1CETP | |
| SCHEMBL4801241 | 0.87 | HSD11B1 (0.48) | UBE2MDCUN1D1OPRM1CETP | |
| SCHEMBL6488479 | 0.86 | OPRM1 (0.40) | OPRM1 | |
| SCHEMBL6488483 | 0.86 | OPRM1 (0.40) | OPRM1 | |
| SCHEMBL6495515 | 0.86 | DPP4 (0.49) | UBE2MDCUN1D1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6495680 | 0.86 | DPP4 (0.49) | UBE2MDCUN1D1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL27596342 | 0.82 | CCR5 (0.48) | CCR5UBE2MDCUN1D1CYP2D6SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919377-B2 | Cyclohexylamine derivative as subtype selective NMDA receptor antagonists | WARNER LAMBERT COMPANY LLC (US) | 2005-07-19 | — | — | US | disclosed |
| US-20030236286-A1 | Cyclohexylamine derivative as subtype selective nmda receptor antagonists | DEORAZIO RUSSELL JOSEPH (US) | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236286-A1 | Cyclohexylamine derivative as subtype selective nmda receptor antagonists | GRIN1, GRIN2A, GRIN2B | CCR5 1576/4885UBE2M 4486/4885DCUN1D1 1720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.